GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Equity-to-Asset

Gritstone Bio (Gritstone Bio) Equity-to-Asset

: 0.29 (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gritstone Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $51.85 Mil. Gritstone Bio's Total Assets for the quarter that ended in Dec. 2023 was $177.77 Mil. Therefore, Gritstone Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.29.

The historical rank and industry rank for Gritstone Bio's Equity-to-Asset or its related term are showing as below:

GRTS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29   Med: 0.77   Max: 0.9
Current: 0.29

During the past 8 years, the highest Equity to Asset Ratio of Gritstone Bio was 0.90. The lowest was 0.29. And the median was 0.77.

GRTS's Equity-to-Asset is ranked worse than
76.18% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs GRTS: 0.29

Gritstone Bio Equity-to-Asset Historical Data

The historical data trend for Gritstone Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only 0.73 0.75 0.78 0.71 0.29

Gritstone Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.67 0.49 0.40 0.29

Competitive Comparison

For the Biotechnology subindustry, Gritstone Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gritstone Bio Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Equity-to-Asset falls into.



Gritstone Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gritstone Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=51.85/177.769
=0.29

Gritstone Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=51.85/177.769
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gritstone Bio  (NAS:GRTS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Gritstone Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gritstone Bio (Gritstone Bio) Business Description

Traded in Other Exchanges
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Executives
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson officer: EVP and General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon director 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142